Literature DB >> 15842654

Molecular mechanisms of fibrinolysis.

Gabriela Cesarman-Maus1, Katherine A Hajjar.   

Abstract

The molecular mechanisms that finely co-ordinate fibrin formation and fibrinolysis are now well defined. The structure and function of all major fibrinolytic proteins, which include serine proteases, their inhibitors, activators and receptors, have been characterized. Measurements of real time, dynamic molecular interactions during fibrinolysis of whole blood clots can now be carried out in vitro. The development of gene-targeted mice deficient in one or more fibrinolytic protein(s) has demonstrated expected and unexpected roles for these proteins in both intravascular and extravascular settings. In addition, genetic analysis of human deficiency syndromes has revealed specific mutations that result in human disorders that are reflective of either fibrinolytic deficiency or excess. Elucidation of the fine control of fibrinolysis under different physiological and pathological haemostatic states will undoubtedly lead to novel therapeutic interventions. Here, we review the fundamental features of intravascular plasmin generation, and consider the major clinical syndromes resulting from abnormalities in fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15842654     DOI: 10.1111/j.1365-2141.2005.05444.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  177 in total

1.  Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects.

Authors:  Sanjeewani T Palayoor; Molykutty J-Aryankalayil; Adeola Y Makinde; David Cerna; Michael T Falduto; Scott R Magnuson; C Norman Coleman
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

2.  Clots Are Potent Triggers of Inflammatory Cell Gene Expression: Indications for Timely Fibrinolysis.

Authors:  Robert A Campbell; Adriana Vieira-de-Abreu; Jesse W Rowley; Zechariah G Franks; Bhanu Kanth Manne; Matthew T Rondina; Larry W Kraiss; Jennifer J Majersik; Guy A Zimmerman; Andrew S Weyrich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-03       Impact factor: 8.311

3.  Plasminogen is a complement inhibitor.

Authors:  Diana Barthel; Susann Schindler; Peter F Zipfel
Journal:  J Biol Chem       Date:  2012-03-27       Impact factor: 5.157

4.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

5.  The effects of whole body vibration and exercise on fibrinolysis in men.

Authors:  Leryn J Boyle; Paul R Nagelkirk
Journal:  Eur J Appl Physiol       Date:  2010-08-05       Impact factor: 3.078

6.  EPAC1 regulates endothelial annexin A2 cell surface translocation and plasminogen activation.

Authors:  Wenli Yang; Fang C Mei; Xiaodong Cheng
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

7.  Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions.

Authors:  Leena Gharat; Govind P Rathod; Shilpa Kandalgaonkar
Journal:  J Int Oral Health       Date:  2013-10-26

8.  Caveolin-1-dependent apoptosis induced by fibrin degradation products.

Authors:  Yi-He Guo; Irene Hernandez; Berend Isermann; Tae-bong Kang; Leonid Medved; Rashmi Sood; Edward J Kerschen; Trudy Holyst; Michael W Mosesson; Hartmut Weiler
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

9.  Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.

Authors:  Norma Torres-Carrillo; Nora Magdalena Torres-Carrillo; Gloria Esther Martínez-Bonilla; Mónica Vázquez-Del Mercado; Claudia Azucena Palafox-Sánchez; Edith Oregón-Romero; Ana Guilaisne Bernard-Medina; Héctor Rangel-Villalobos; José Francisco Muñoz-Valle
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

10.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.